Experimental vaccine targets Hard-to-Treat colorectal cancer
NCT ID NCT07510308
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new vaccine made from genetically modified tumor cells in 9 adults with advanced pMMR colorectal cancer who have run out of standard options. The vaccine is given as a series of injections to see if it is safe and can stimulate the immune system to fight the cancer. The main goal is to check for side effects, with a secondary look at whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MSH2-/- tumor cell vaccine
What this could lead to
If it works, this could point toward a new treatment option for advanced colorectal cancer that has not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it is primarily testing safety, not effectiveness. The vaccine may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PMMR/MSS ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China